News headlines about SeaSpine (NASDAQ:SPNE) have trended somewhat positive on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SeaSpine earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 47.0447879099988 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of SeaSpine (SPNE) traded down $0.01 on Wednesday, reaching $9.99. The company’s stock had a trading volume of 26,975 shares, compared to its average volume of 37,168. The company has a market cap of $145.38, a price-to-earnings ratio of -3.83 and a beta of 0.36. SeaSpine has a 52-week low of $6.31 and a 52-week high of $13.46.
SeaSpine (NASDAQ:SPNE) last announced its quarterly earnings data on Wednesday, February 28th. The medical equipment provider reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.04). The firm had revenue of $33.98 million during the quarter. SeaSpine had a negative net margin of 24.36% and a negative return on equity of 29.96%. equities analysts predict that SeaSpine will post -1.99 earnings per share for the current year.
SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment.
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.